Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways release_s2kv7pqobzgtzdhiuaulowyyd4

by Junjia Zhang, Jichun Yu, Rong Xie, Wanzhi Chen, Yunxia Lv

Published by Figshare.

2016  

Abstract

The objective of this study was to examine the <i>in vitro</i> combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells FTC133 using a MTT cytotoxicity assay, and to test whether the mechanism involves induction of apoptosis. The present results demonstrated that curcumin at 15–25 μM dose-dependently suppressed the proliferation of FTC133. Combined treatment (curcumin (25 μM) and sorafenib (2 μM)) resulted in a reduction in cell colony formation and significantly decreased the invasion and migration of FTC133 cells compared with that treated with individual drugs. Western blot showed that the levels of p-ERK and p-Akt proteins were significantly reduced (<i>p</i>
In text/plain format

Archived Files and Locations

application/pdf  193.0 kB
file_mke35hd33nc6titeocyv6l6afy
web.archive.org (webarchive)
s3-eu-west-1.amazonaws.com (publisher)
Read Archived PDF
Archived
Type  article-journal
Stage   published
Date   2016-08-07
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: a1258ffd-f393-4f34-9d3e-20d5010f22aa
API URL: JSON